Synchron

Synchron is a neurotechnology company headquartered in New York that develops brain-computer interfaces designed to restore digital communication and control for people with paralysis. The company's flagship product, the Stentrode, is a minimally invasive implantable device delivered directly through the jugular vein without requiring open-brain surgery. Once implanted in blood vessels adjacent to the motor cortex, the Stentrode detects neural signals that users can harness to operate computers, communication software, and other digital devices through thought alone. This endovascular approach represents a significant departure from traditional BCI methods, offering patients a safer alternative with reduced surgical risks and recovery time.

Synchron achieved a major milestone in 2021 when the FDA granted its Stentrode Breakthrough Device Designation, recognizing the technology's potential to address an unmet medical need for paralyzed patients. The company has demonstrated clinical efficacy through human trials showing that paralyzed patients can successfully use the device to perform digital tasks like typing and web browsing. With Series B funding of $75 million, Synchron has secured the capital needed to advance toward broader clinical trials and eventual commercialization, positioning itself as a serious contender in the competitive BCI market.

Synchron matters to the neurotech industry because it has solved a critical engineering challenge that has long limited BCI adoption: delivering a sophisticated neural interface without the risks and costs associated with invasive brain surgery. By proving that endovascular delivery is viable, the company has opened a new pathway for neural interface development that could dramatically expand patient access to BCI technology. The Stentrode's success could influence how the entire industry approaches minimally invasive approaches to neural interfacing, potentially accelerating the timeline for bringing effective BCIs to the millions of people worldwide living with paralysis.